Our top pick for
McDermott International Inc is an other business based in the US. McDermott International shares (MDR) are listed on the NYSE and all prices are listed in US Dollars. McDermott International employs 31,900 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$0.00 - $0.00|
|50-day moving average||$0.07|
|200-day moving average||$1.22|
|Wall St. target price||$9.09|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-16.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing McDermott International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of McDermott International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
McDermott International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.88. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into McDermott International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
McDermott International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $282 million.
The EBITDA is a measure of a McDermott International's overall financial performance and is widely used to measure a its profitability.
|Gross profit TTM||$601 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$131.7 million|
TTM: trailing 12 months
We're not expecting McDermott International to pay a dividend over the next 12 months.
McDermott International, Inc. provides engineering, procurement, construction and installation, and technology solutions to the energy industry worldwide. It operates through five segments: North, Central and South America; Europe, Africa, Russia and Caspian; the Middle East and North Africa; Asia Pacific; and Technology. It designs, engineers, and constructs upstream offshore oil and gas facilities, downstream oil and gas facilities, gas-fired power plants, liquefied natural gas import and export terminals, atmospheric and refrigerated storage vessels and terminals, water storage and treatment facilities, pipe and module fabrication, hydrocarbon processing facilities, pipe fabrication and manufacturing, and refining and petrochemical facilities. The company also provides gas processing, refining, petrochemical and coal gasification technologies, as well as a supplies catalysts, equipment, and related engineering services. It serves national, integrated, and other oil and gas companies, as well as producers of petrochemicals and electric power. McDermott International, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.